Morgan Xu
Director/Board Member at Renova Therapeutics, Inc.
Profile
Morgan Xu is currently a Director at Renova Therapeutics, Inc. He has an undergraduate degree from Fudan University, an MBA and a doctorate from Harvard Business School, and an undergraduate degree from Harvard College.
Morgan Xu active positions
| Companies | Position | Start |
|---|---|---|
Renova Therapeutics, Inc.
 Renova Therapeutics, Inc. BiotechnologyHealth Technology Renova Therapeutics, Inc. operates as a biopharmaceutical company. The firm is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. Its product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in patients with CHF. The company was founded by Jack W. Reich, H. Kirk Hammond and Craig Andrews in 2009 and is headquartered in San Diego, CA. | Director/Board Member | - |
Training of Morgan Xu
| Harvard College | Undergraduate Degree |
| Harvard Business School | Doctorate Degree |
| Fudan University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Renova Therapeutics, Inc.
Renova Therapeutics, Inc. BiotechnologyHealth Technology Renova Therapeutics, Inc. operates as a biopharmaceutical company. The firm is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. Its product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in patients with CHF. The company was founded by Jack W. Reich, H. Kirk Hammond and Craig Andrews in 2009 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Morgan Xu
